Savara is a biopharmaceutical company developing MOLBREEVI, an inhaled investigational drug for a rare lung disease. SVRA reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 7 | JP Morgan | Initiated | Buy |
Seasonality
How SVRA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
Whale Options Flow
90DNo whale options trades in SVRA in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SVRA is in one of them and how their past SVRA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SVRA in an article yet. Here's the latest on the wider market.
About Savara
Savara is a biopharmaceutical company that develops treatments for rare respiratory diseases. Its main product candidate, MOLBREEVI, is an investigational inhaled drug for patients with autoimmune pulmonary alveolar proteinosis, a rare lung disease in which a substance called surfactant builds up in the air sacs of the lungs. The drug is given through a nebulizer device and is not yet approved for sale. The company is based in Austin, Texas.
- Headquarters
- Austin, TX